Table 1.
List of variables that are known to be associated with differences in survival in lower grade glioma patients. 11 variables (bolded) were selected by Lasso for inclusion in the survival model. We used these 11 variables as covariates in our Cox regression model when testing each germline variant.
| Covariate | Median (Min-Max) or Number of Patients | |
|---|---|---|
| Age | 41 (14 - 87) | |
| Gender | Female | 250 |
| Male | 200 | |
| Somatic Mutation Count | 50 (0 - 12255) | |
| Percent Aneuploidy | 11% (5.2E-4% - 95%) | |
| log(TERT Expression) | 1.0 (0.0 - 9.1) FPKM | |
| Principle Component 1 (PC1) | 0.043 (−0.091 - 0.064) | |
| Principle Component 2 (PC2) | −0.017 (−0.23 - 0.17) | |
| Principle Component 3 (PC3) | −0.53 (1.34E-4 - 0.33) | |
| Histological Type | Astroctyoma | 172 |
| Oligoastrocytoma | 113 | |
| Oligodendroglioma | 165 | |
| Tumor Location | Frontal Lobe | 265 |
| Temporal Lobe | 125 | |
| Parietal Lobe | 42 | |
| Other | 18 | |
| Grade | G2 | 212 |
| G3 | 237 | |
| Cannot Be Assessed | 1 | |
| Treatment Site | Henry Fords Hospital | 82 |
| Case Western St. Joes | 90 | |
| Other | 278 | |
| IDH Mutant | Wild Type | 83 |
| Mutant | 367 | |
| 1p/19q Co-deletion | Absent | 303 |
| Present | 147 | |
| MGMT Promoter Methylation | Unmethylated | 80 |
| Methylated | 370 | |
| Chr 7 gain/Chr 10 loss | Absent | 399 |
| Present | 51 | |
| TP53 Mutant | Absent | 232 |
| Present | 218 | |